1483O Results of a phase I/II combination regimen with ipilimumab ...

These data suggest that first-line combinatorial therapy with Ipilimumab, Nivolumab and Trabectedin may be (1) More effective than standard first line therapy, ...

SARCOMA - Annals of Oncology

1483O. Results of a phase I/II combination regimen with ipilimumab. (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma. E ...

ESMO 2022: Results of a phase I/II combination regimen with ...

1483O - Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma ...

Invited Discussant 1482O and 1483O - OncologyPRO

1483O - Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma.

Walter Andree Tellez's research works | Sarcoma Oncology Center ...

1483O Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma.

Victoria S. Chua-Alcala's research works | Sarcoma Oncology ...

... Evidence of a synergistic interaction between these treatment types remains lacking. Survival updates for phase 2 trials using nivolumab, ipilimumab, and ...

ESMO Congress 2022 | OncologyPRO

1483O - Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma.

‪Walter Andree Tellez MD‬ - ‪Google Scholar‬

1483O Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma. E ...

‪Walter Andree Tellez MD‬ - ‪Google Scholar‬

1483O Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma. E ...

Innovations & Thérapeutiques en Oncologie - Key moments in ... - JLE

1483O Results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced leiomyosarcoma.

A Phase I/II Trial of Nivolumab plus Ipilimumab in Children ... - PubMed

The RP2D of nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) is well tolerated in children and young adults with solid tumors and shows some ...

Therapeutic advances in leiomyosarcoma - Frontiers

1483O - results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for ...

Combination Therapy and the Role of Cytoreductive Surgery - PMC

Checkpoint inhibitor-based combination therapy was evaluated in the phase III Checkmate 214 trial, which compared combined therapy with nivolumab-ipilimumab to ...

Therapeutic advances in leiomyosarcoma - OUCI

Gordon, 1483O - results of a phase I/II combination regimen with ipilimumab (I), nivolumab (N) and trabectedin (T) as first line therapy for advanced ...

Advances In First Line Therapy For Metastatic Clear Cell Renal Cell ...

The primary outcome was progression-free survival with overall survival, objective response rate, and toxicity comprising important secondary outcomes.

A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib ...

FIGURE 2. Base case acceptability curve for nivolumab-ipilimumab and pembrolizumab-axitinib combination therapy and sunitinib monotherapy from 10,000 Monte ...

18n2_a1 | KCJ - Kidney Cancer Journal

16 This study validated the benefit of pembrolizumab + axitinib combination therapy. Similarly, pembrolizumab monotherapy for treatment naïve patients has also ...

Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma

While these new front-line regimens are associated with reliably high response rates and prolonged survival, complete and durable remissions remain limited to a ...

Pembrolizumab in Combination with Axitinib as First-Line Treatment ...

Abstract: Over the last 18 months, 3 immunotherapy combination regimens (ipilimumab + ... high-dose interleukin-2 therapy and impact on survival in patients with ...

Clear-cell renal cell carcinoma - A comprehensive review of agents ...

Nivolumab for metastatic renal cell carcinoma: results of a randomized phase. II trial. ... Safety and effica- cy of nivolumab in combination with ipilimumab ...